Arimidex (anastrozole) is now approved as first-line therapy of advanced breast cancer
July 2000
Arimidex (anastrozole) is now approved as first-line therapy of advanced breast cancer in Canada. It's still second-line in the U.S.
It's an alternative to tamoxifen for postmenopausal women with estrogen receptor-positive breast cancer.
Until now, Arimidex was approved only as second-line therapy...when breast cancer progressed despite treatment with tamoxifen.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive